These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38771515)

  • 1. STING-targeted PET imaging: unveiling tumor immunogenicity post-chemotherapy in colorectal cancer.
    Li C; Saladin RJ; Cai W; Chen W
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2758-2760. PubMed ID: 38771515
    [No Abstract]   [Full Text] [Related]  

  • 2. STING-targeted PET tracer for early assessment of tumor immunogenicity in colorectal cancer after chemotherapy.
    Xu D; Lu X; Yang F; Jiang Z; Yang S; Bi L; Liu J; Shan H; Li D
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):641-655. PubMed ID: 37924341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING-Targeted PET Imaging for Specific Detection and Therapeutic Monitoring of Myocarditis.
    Ye Z; Lu X; Zhu M; Bi L; Yang F; Zhou B; Xu D; Yao L
    Mol Pharm; 2024 Jun; 21(6):2865-2877. PubMed ID: 38666508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel STING-targeted PET radiotracer for alert and therapeutic evaluation of acute lung injury.
    Xu D; Yang F; Chen J; Zhu T; Wang F; Xiao Y; Liang Z; Bi L; Huang G; Jiang Z; Shan H; Li D
    Acta Pharm Sin B; 2023 May; 13(5):2124-2137. PubMed ID: 37250155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fluorine-18-2-deoxy-2-fluoro-D-glucose positron emission tomography in colorectal cancer].
    Tang G; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2005 Feb; 22(1):193-6, 201. PubMed ID: 15762148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of
    Liu H; Sun Y; Li J; Chen Y; Liu J; Fang J; Yang H; Feng L; Peng S; Zhuang R; Guo Z; Zhang X
    Mol Pharm; 2023 Jul; 20(7):3529-3538. PubMed ID: 37243620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases.
    Glazer ES; Beaty K; Abdalla EK; Vauthey JN; Curley SA
    Arch Surg; 2010 Apr; 145(4):340-5; discussion 345. PubMed ID: 20404283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel
    Fang J; Feng L; Meng L; Wang X; Liu H; Huang L; Zhang D; Li J; Zhuang R; Guo Z; Zhang X
    Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):27-37. PubMed ID: 36066666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer.
    Larson SM; Schoder H; Yeung H
    Cancer J; 2004; 10(4):243-50. PubMed ID: 15383205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent chemotherapy reduces the maximum-standardized uptake value of 18F-fluoro-deoxyglucose positron emission tomography in colorectal cancer.
    Lee M; Yeum TS; Kim JW; Oh S; Lee SA; Moon HR; Choi YH; Han YM; Choi JM; Jang DK
    Gut Liver; 2014 May; 8(3):254-64. PubMed ID: 24827621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [
    Liang K; Abt ER; Le TM; Cho A; Dann AM; Cui J; Li L; Rashid K; Creech AL; Wei L; Ghukasyan R; Rosser EW; Wu N; Carlucci G; Czernin J; Donahue TR; Radu CG
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34480004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET: for early prediction of response to the first-line chemotherapy in metastatic colorectal cancer?
    Arslan C; Kilickap S
    Ann Oncol; 2009 Jun; 20(6):1149-50; author reply 1150. PubMed ID: 19465432
    [No Abstract]   [Full Text] [Related]  

  • 13.
    Fang J; Zhang J; Meng L; Li H; Xia D; Wang Y; Chen H; Liao Z; Zhuang R; Li Y; Zhang X; Guo Z
    Mol Pharm; 2024 Apr; 21(4):1942-1951. PubMed ID: 38447198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.
    Byström P; Berglund A; Garske U; Jacobsson H; Sundin A; Nygren P; Frödin JE; Glimelius B
    Ann Oncol; 2009 Jun; 20(6):1057-61. PubMed ID: 19164458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases.
    Zissen MH; Kunz P; Subbarayan M; Chin FT; Conti PS; Fisher GA; Quon A
    Nucl Med Commun; 2011 May; 32(5):343-7. PubMed ID: 21412178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET.
    Francis DL; Visvikis D; Costa DC; Croasdale I; Arulampalam TH; Luthra SK; Taylor I; Ell PJ
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):928. PubMed ID: 15034675
    [No Abstract]   [Full Text] [Related]  

  • 17. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review.
    de Geus-Oei LF; Vriens D; van Laarhoven HW; van der Graaf WT; Oyen WJ
    J Nucl Med; 2009 May; 50 Suppl 1():43S-54S. PubMed ID: 19403879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
    Pelosi E; Deandreis D
    Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography and colorectal cancer.
    Lin M; Wong K; Ng WL; Shon IH; Morgan M
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):30-47. PubMed ID: 20619671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.